TELA Stock Forecast: TELA Bio, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for TELA Bio, Inc. is $2. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 36 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores TELA Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (82): Reported profit is backed by cash, and the company is not expanding recklessly.
Issuance (8): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
TELA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on TELA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 25 Sept 2026 | Craig-Hallum | Initiates | Buy | $2.00 |
| 27 Mar 2026 | Citizens | Maintains | Market Outperform | $5.00 → $3.00 |
| 25 Mar 2026 | Canaccord Genuity | Maintains | Buy | $4.00 → $2.00 |
| 25 Mar 2026 | Lake Street | Maintains | Buy | $3.00 → $2.00 |
| 25 Mar 2026 | Piper Sandler | Maintains | Neutral | $1.25 → $1.00 |
| 1 Dec 2025 | Lake Street | Maintains | Buy | — |
| 18 Nov 2025 | Canaccord Genuity | Maintains | Buy | — |
| 14 Nov 2025 | Citizens | Maintains | Market Outperform | — |
| 14 Nov 2025 | Piper Sandler | Reiterates | Neutral | — |
| 21 Mar 2025 | Canaccord Genuity | Maintains | Buy | — |
| 21 Mar 2025 | Citizens Capital Markets | Maintains | Market Outperform | — |
| 21 Mar 2025 | Piper Sandler | Downgrade | Neutral | — |
| 8 Nov 2024 | Piper Sandler | Maintains | Overweight | — |
| 4 Oct 2024 | Canaccord Genuity | Maintains | Buy | — |
| 13 Aug 2024 | Canaccord Genuity | Maintains | Buy | — |
| 13 Aug 2024 | JMP Securities | Maintains | Market Outperform | — |
| 13 Aug 2024 | Lake Street | Maintains | Buy | — |
| 13 Aug 2024 | Piper Sandler | Maintains | Overweight | — |
| 25 July 2024 | Canaccord Genuity | Maintains | Buy | — |
| 10 May 2024 | Piper Sandler | Reiterates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for TELA.
This page is one stock. Monday covers all of them.
TELA appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
TELA vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, TELA Bio, Inc. returned −35.0% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
TELA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 0.5×
- Price / book
- —
- EV / EBITDA
- —
Cheaper than 80% of US stocks
- Revenue growth (YoY)
- −8.4%
- Earnings growth (YoY)
- —
- Gross margin
- 72.3%
- Operating margin
- −40.5%
- Net margin
- −53.6%
Higher than 18% of US stocks
Higher than 85% of US stocks
Higher than 19% of US stocks
Higher than 10% of US stocks
- Return on equity
- —
- Return on assets
- −35.6%
- Dividend yield
- —
Higher than 12% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
TELA Bio, Inc. has a market value of $32.8M and an enterprise value of $68.2M.
Revenue in the twelve months to 30 June 2026: $79.9M. The latest quarter shrank 4.5% year on year.
Net income over the same four quarters: −$41.2M, a −51.5% net margin.
Diluted earnings per share, trailing twelve months: −$0.77.
Free cash flow in the twelve months to 30 June 2026: −$31.6M.
TELA Bio, Inc. employs 218 people — $367K of revenue per employee.
Data provided by Twelve Data
TELA and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at TELA’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own TELA Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about TELA
What is the TELA stock price forecast for 2026-2027?
The median 12-month analyst price target for TELA Bio, Inc. is $2. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is TELA stock a buy right now?
Of the 3 analysts covering TELA Bio, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks TELA Bio, Inc. 36 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank TELA?
As at 21 Nov 2026, TELA Bio, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (82 of 100).
Will TELA stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts is $2, and Ticker Nerd's factor model ranks TELA Bio, Inc. 36 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the TELA stock forecast for 2030?
No analyst covering TELA Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TELA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $2 over the next 12 months.
How has TELA stock performed over the past year?
TELA Bio, Inc. returned -35.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does TELA Bio, Inc. do?
TELA Bio, Inc. is a commercial-stage medical technology company focused on soft-tissue reconstruction solutions for surgeons and healthcare providers. The company develops and markets reinforced tissue matrix products designed for hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery, with an emphasis on preserving and restoring the patient’s own anatomy.
About TELA Bio, Inc.
TELA Bio, Inc. is a commercial-stage medical technology company focused on soft-tissue reconstruction solutions for surgeons and healthcare providers. The company develops and markets reinforced tissue matrix products designed for hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery, with an emphasis on preserving and restoring the patient’s own anatomy. Its OviTex portfolio includes products for open, laparoscopic, and robotic procedures, as well as configurations tailored to different surgical needs in general surgery and reconstructive care. TELA Bio also supports applications that aim to reduce reliance on permanent synthetic materials while leveraging the body’s natural healing response. Headquartered in Malvern, Pennsylvania, TELA Bio serves the medical device market through products that address unmet needs in modern soft-tissue repair.
CEO Ms. Heather C. Getz CPA, M.B.A. · 218 employees · United States · https://www.telabio.com